Karyopharm announces presentation of updated exploratory subgroup analyses from siendo study in patients with advanced or recurrent tp53 wild-type endometrial cancer

Signal of pfs improvement in siendo for selinexor-treated patients was observed only in subgroup who are tp53 wild-type with a median progression-free survival of 27.4 months  median pfs not reached for selinexor-treated patients who are tp53 wild-type mss (pmmr)  updated analysis provides further rationale for xport-ec-042, the ongoing pivotal phase 3 study (nct05611931) evaluating selinexor as maintenance therapy in tp53 wild-type endometrial cancer newton, mass. , july 25, 2023 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq: kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the presentation of updated exploratory subgroup analyses from the siendo study (nct03555422) in patients with advanced or recurrent tp53 wild-type endometrial cancer at the virtual american society of clinical oncology (asco) plenary series.
KPTI Ratings Summary
KPTI Quant Ranking